K Borchert - Concepedia

Author

K Borchert

Heidelberg University ORCID

Also Known As

Borchert K, Borchert, Kersten, K BORCHERT, K Borchert, K. BORCHERT, K. Borchert, KERSTEN BORCHERT, Kersten Borchert

Publications

864

Citations

H-Index

Concepts

All Affiliations

Heidelberg University University of Rostock University Hospital Frankfurt Goethe University Frankfurt University Hospital Heidelberg

About

K Borchert is an author at Heidelberg University specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	206
2	Clinical Nutrition	2	2	184
3	Gastroenterology	2	2	184
4	Health Sciences	1	1	83
5	Public Health	1	1	110

K Borchert

Publications

831

Citations

H-Index

Page 1

	Year	Citations
Forty-one recent cases of invasive zygomycosis from a global clinical registry Maria J. G. T. Rüping, Werner Heinz, A. J. Kindo, Journal of Antimicrobial Chemotherapy	2009	199
Effect of glutamine-enriched total parenteral nutrition in patients with acute pancreatitis Johann Ockenga, K Borchert, K. Rifai, Clinical Nutrition NutritionNutritional RequirementBiochemical NutritionClinical NutritionGastroenterology	2002	110
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER) Markus Moehler, Annett Maderer, Peter Thuss‐Patience, Annals of Oncology	2020	110
FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group Ralf‐Dieter Hofheinz, Kirsten Merx, Georg Martin Haag, Journal of Clinical Oncology	2022	86
Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO. Ralf‐Dieter Hofheinz, Georg Martin Haag, Thomas J. Ettrich, Journal of Clinical Oncology Surgical OncologyEsophageal CancerCancer ManagementSurgeryPharmacotherapy	2020	83
Glutamine-enriched total parenteral nutrition in patients with inflammatory bowel disease Johann Ockenga, K Borchert, E. Stüber, European Journal of Clinical Nutrition NutritionFood IntoleranceClinical NutritionGastroenterologyMedical Nutrition Therapy	2005	74
A Comprehensive Analysis of the Cellular and EBV-Specific MicroRNAome in Primary CNS PTLD Identifies Different Patterns Among EBV-Associated Tumors Susanne Fink, Maher K. Gandhi, Jamie P. Nourse, American Journal of Transplantation	2014	58
Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors Michael Schmitt, Xiangdong Xu, Inken Hilgendorf, Bone Marrow Transplantation	2013	26
1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma S-E. Al-Batran, Georg-Martin Haag, Thomas J. Ettrich, Annals of Oncology Surgical OncologyGastrointestinal OncologyMedicineFlot Versus FlotSurgery	2020	26
Forty-One Recent Cases of Invasive Zygomycosis From a Global Clinical Registry. Maria J.G.T. Rueping, Werner Heinz, Anupma Jyoti Kindo, Blood	2009	15

Page 1